← Leaderboards
Israel Lowy
Medarex, Inc.
$7,197,782
Attributed
$7,197,782
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $786.9K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$7,197,782 · 2
By mechanism
UC1$4,863,738 · 1
U01$2,334,044 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Monoclonal Antibody”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$276,346,332
- Lawrence Corey · Fred Hutchinson Cancer Center$271,417,082
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$257,261,947
- Peter B. Gilbert · Fred Hutchinson Cancer Center$190,281,881
- Barton F Haynes · Duke University$125,632,198
Research focus
Monoclonal AntibodyImmunologic Substance Development /PreparationAnthrax ToxinPassive ImmunizationAntitoxinsLaboratory RabbitPharmacokineticsMacaca FascicularisCommunicable Disease ControlConfocal Scanning MicroscopyCooperative StudyDisease /Disorder ModelDrug Adverse EffectAnthraxHuman SubjectHuman Therapy EvaluationImmune ResponseImmunityImmunopharmacologyImmunotherapyNeutralizing AntibodyNonhuman Therapy EvaluationPatient Oriented ResearchHuman Genetic Material Tag
Grant awards (4)
Development of Fully Human mAbs as Anthrax Antitoxins$766,020
U01 · FY2006 · AI · contact PI
Development of Fully Human mAbs as Anthrax Antitoxins$786,931
U01 · FY2005 · AI
Fully Human Anti-Anthrax Toxin MAbs: Product Development$4,863,738
UC1 · FY2004 · AI
Development of Fully Human mAbs as Anthrax Antitoxins$781,093
U01 · FY2004 · AI